...
首页> 外文期刊>MIMS Doctor. >Oral semaglutide trumps sitagliptin in reducing HbA1c, weight in uncontrolled T2D
【24h】

Oral semaglutide trumps sitagliptin in reducing HbA1c, weight in uncontrolled T2D

机译:口服semaglutide胜过sitagliptin在减少在不受控制的T2D糖化血红蛋白、体重

获取原文
获取原文并翻译 | 示例
           

摘要

Individuals with poorly controlled type 2 diabetes (T2D) had greater HbAlc reductions and weight loss when a 7 or 14 mg/day dose of the GLP-1* receptor agonist semaglutide rather than sitagliptin was added to their background diabetic medications, results of the phase Ilia PIONEER 3** trial showed.
机译:患有2型糖尿病控制不佳(T2D)大HbAlc减少和体重当7或损失GLP-1 * 14毫克/天的剂量受体激动剂semaglutide而不是sitagliptin添加到他们的背景糖尿病药物,髂骨阶段的结果先锋3 * *试验显示。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号